Brief: FDA Approves Cell Therapy For Patients With Blood Cancers To Reduce Risk Of Infection Following Stem Cell Transplantation

Gamida Cell

17/04/2023 19:40

April 17 (Reuters) - FDA:
    * FDA APPROVES CELL THERAPY FOR PATIENTS WITH BLOOD CANCERS
TO
REDUCE RISK OF INFECTION FOLLOWING STEM CELL TRANSPLANTATION
    * FDA - APPROVED OMISIRGE TO QUICKEN RECOVERY OF NEUTROPHILS
(A
SUBSET OF WHITE BLOOD CELLS) IN THE BODY AND REDUCE THE RISK OF
INFECTION
    * FDA: PRODUCT INTENDED FOR USE IN PATIENTS WITH BLOOD
CANCERS
PLANNED FOR UMBILICAL CORD BLOOD TRANSPLANTATION AFTER
MYELOABLATIVE CONDITIONING REGIMEN

Source text for Eikon:  ID: 

 ((Reuters.Briefs@thomsonreuters.com;))